Over the next two years, we will pursue research on the association between brain waves and genetics in ADHD patients. This will contribute to the quantification of ADHD diagnosis based on bio-big data.
On November 8th, healthcare company DNA Corporation (DNA) partnered with Hills Mental Health Clinic (Hills), a mental health clinic specializing in mental health, to conduct a joint study on the correlation between brain waves and genetic markers in ADHD patients.
The two organizations signed a joint research and development agreement. The agreement includes: collaboration for clinical research advancement; medical and academic advice on research results; strategic advice for clinical development and clinical research in each field; and collaboration on hosting related events such as clinical trial seminars, forums, and conferences.
With this agreement, DNA will expand its R&D scope beyond existing ADHD screening tests to include brainwave-based bio big data analysis. DNA will work with Hills to study the correlation between genetic biomarkers and brain waves, thereby defining optimal patient populations, identifying disease targets, and applying its technology to derivative research.
(Omitted)
DNA CEO Ko Kyung-hwan and Hills Mental Health Clinic Director Kim Hye-ji stated, "This will serve as a starting point for shifting the existing paradigm of 'presumptive diagnosis and diagnosis after the onset of a problem' in the field of ADHD diagnosis to one of evidence-based and early diagnosis. It will contribute to diversifying ADHD diagnostic methods. Considering that ADHD diagnosis was previously conducted in a question-and-answer format, this will enable a more objective, evidence-based diagnosis, rather than a diagnosis based solely on subjective answers based on individual patient understanding."
They added, "While medical professionals have been cautious about mentioning the possibility of ADHD, presenting objective results will alleviate the burden of the medical team's personal opinion. Saliva-based ADHD testing can be performed immediately, even in infancy, enabling rapid diagnosis. Rapidly identifying ADHD risk factors in infancy will allow for various early interventions, including lifestyle modifications, environmental adjustments, and behavioral therapy, contributing to lower social costs." They emphasized, "We hope that a preventative approach to ADHD will one day be possible."
Original text: http://www.biotimes.co.kr/news/articleView.html?idxno=12767
Over the next two years, we will pursue research on the association between brain waves and genetics in ADHD patients. This will contribute to the quantification of ADHD diagnosis based on bio-big data.
On November 8th, healthcare company DNA Corporation (DNA) partnered with Hills Mental Health Clinic (Hills), a mental health clinic specializing in mental health, to conduct a joint study on the correlation between brain waves and genetic markers in ADHD patients.
The two organizations signed a joint research and development agreement. The agreement includes: collaboration for clinical research advancement; medical and academic advice on research results; strategic advice for clinical development and clinical research in each field; and collaboration on hosting related events such as clinical trial seminars, forums, and conferences.
With this agreement, DNA will expand its R&D scope beyond existing ADHD screening tests to include brainwave-based bio big data analysis. DNA will work with Hills to study the correlation between genetic biomarkers and brain waves, thereby defining optimal patient populations, identifying disease targets, and applying its technology to derivative research.
(Omitted)
DNA CEO Ko Kyung-hwan and Hills Mental Health Clinic Director Kim Hye-ji stated, "This will serve as a starting point for shifting the existing paradigm of 'presumptive diagnosis and diagnosis after the onset of a problem' in the field of ADHD diagnosis to one of evidence-based and early diagnosis. It will contribute to diversifying ADHD diagnostic methods. Considering that ADHD diagnosis was previously conducted in a question-and-answer format, this will enable a more objective, evidence-based diagnosis, rather than a diagnosis based solely on subjective answers based on individual patient understanding."
They added, "While medical professionals have been cautious about mentioning the possibility of ADHD, presenting objective results will alleviate the burden of the medical team's personal opinion. Saliva-based ADHD testing can be performed immediately, even in infancy, enabling rapid diagnosis. Rapidly identifying ADHD risk factors in infancy will allow for various early interventions, including lifestyle modifications, environmental adjustments, and behavioral therapy, contributing to lower social costs." They emphasized, "We hope that a preventative approach to ADHD will one day be possible."
Original text: http://www.biotimes.co.kr/news/articleView.html?idxno=12767